Companies such as Biosynth (Switzerland), Bachem AG (Switzerland), Bicycle Therapeutics (U.K.), CHIESI Farmaceutici S.p.A. (Italy) and Creative Peptides (U.S.) are the major companies in the constrained peptide drugs market.
In January 2025, Bicycle Therapeutics plc announced updated topline Phase 1 combination data for zelenectide pevedotin plus pembrolizumab in previously untreated, cisplatin-ineligible patients with metastatic urothelial cancer (mUC). In October 2023, UCB announced that the U.S. Food and Drug Administration (FDA) had approved ZILBRYSQ (zilucoplan) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody-positive.
The countries covered in the constrained peptide drugs market are U.S., Canada and Mexico, Germany, France, U.K., Italy, Russia, Spain, Denmark, Sweden, Norway, Rest of Europe, China, Japan, India, South Korea, Australia, Thailand, Rest of Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Nigeria, Egypt, Kuwait, Rest of Middle East and Africa, Brazil, Argentina and Rest of South America
Corporate Email ID Only (Avoid Using Generic mail ID such as Gmail)
Consent Preferences
We use cookies to improve your experience We use cookies to deliver the best possible experience on our website. To learn more, visit our Privacy Policy. By continuing to use this site, or closing this box, you consent to our use of cookies. Cookie Notice.
The data presented is for visualization purposes only and may not reflect actual results.